English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  While COVID-19 carries substantial morbidity and mortality, the extent of long-term complications remains unclear. Reports suggest that acute lung damage associated with severe COVID-19 can result in chronic respiratory dysfunction. This study: (1) estimated the incidence of dyspnea and ILD after COVID-19 hospitalization, and (2) assessed risk factors for developing dyspnea and ILD in a real-world cohort of patients hospitalized with COVID-19 using US electronic health records (EHR).    Methods  Patients in the Optum de-identified COVID-19 EHR database who were hospitalized for COVID-19 (lab confirmed or diagnosis code) between February 20 and July 2020 and had at least 6 months of follow-up were eligible for analysis. Dyspnea and ILD were identified using diagnosis codes. The effects of baseline characteristics and hospitalization factors on the risk of incident dyspnea or ILD 3 to 6 months’ post discharge were evaluated.Results  Among eligible patients (n=26,339), 1705 (6.5%) had dyspnea and 220 (0.8%) had ILD 3 to 6 months after discharge. Among patients without prior dyspnea or ILD (n=22,613), 110 (0.5%) had incident ILD ( Table 1 ) and 1036 (4.6%) had incident dyspnea ( Table 2 ) 3 to 6 months after discharge. In multivariate analyses, median (IQR) length of stay (LOS; 5.0 [3.0, 9.0] days in patients who did not develop ILD vs 14.5 [6.0, 26.0] days in patients who developed ILD; RR: 1.12, 95% CI: 1.08, 1.15;  P =4.34 x 10 -10 ) and age (RR: 1.02, 95% CI: 1.01, 1.03;  P =4.63 x 10 -3 ) were significantly associated with ILD. Median (IQR) LOS (5.0 [3.0, 9.0] days in patients who did not develop dyspnea vs 7 [4.0, 14.0] days in patients who developed dyspnea; RR: 1.04, 95% CI: 1.02, 1.06;  P =8.52 x 10 -4 ), number of high-risk comorbidities (RR: 1.18, 95% CI: 1.12, 1.24;  P =3.85 x 10 -9 ), and obesity (RR: 1.52, 95% CI: 1.25, 1.86;  P =2.59 x 10 -4 ) were significantly associated with dyspnea.  Table 1. Selected Baseline Risk Factors for Incident ILDTable 2. Selected Baseline Risk Factors for Incident DyspneaConclusion  In a real-world cohort, 4.6% and 0.5% of patients developed dyspnea and ILD, respectively, after COVID-19 hospitalization. Multivariate analyses suggested that LOS, age, obesity, and comorbidity burden may be risk factors for post-COVID-19 respiratory complications. Limitations included sensitivity of diagnosis codes, availability of labs, and care-seeking bias.    Disclosures    Kelly Zalocusky, PhD ,  F. Hoffmann-La Roche Ltd  (Shareholder) Genentech, Inc.  (Employee)  Devika Chawla, PhD MSPH ,  F. Hoffmann-La Roche Ltd.  (Shareholder) Genentech, Inc.  (Employee)  Margaret Neighbors, PhD ,  F. Hoffmann-La Roche Ltd  (Shareholder) Genentech, Inc.  (Employee)  Shemra Rizzo, PhD ,  F. Hoffmann-La Roche Ltd.  (Shareholder) Genentech, Inc.  (Employee)  Larry Tsai, MD ,  F. Hoffmann-La Roche Ltd  (Shareholder) Genentech, Inc.  (Employee)

open forum infectious diseases

26. Risk of Post–COVID-19 Dyspnea and Interstitial Lung Disease (ILD) in a Real-World Cohort of Patients Hospitalized with COVID-19 in the United States